title: ProC Global assay in the evaluation of women with history of severe preeclampsia or HELLP syndrome.
abstract: Preeclampsia/HELLP syndrome has been associated with a high incidence of defects in the protein C pathway and increased anticardiolipin-antibodies/lupus anticoagulants. It is also apparent that thrombophilia is responsible for other pregnancy complications, such as recurrent spontaneous abortion, fetal growth restriction, intrauterine fetal death, and abruptio placentae. ProC Global is a new global dotting assay designed to evaluate the abnormalities in the protein C anticoagulant pathway. It is based on the ability of endogenous activated protein C, generated by activation of protein C by Protac, to prolong an activated partial thromboplastin time. A total of 61 patients with a history of severe preeclampsia or HELLP syndrome and 61 normal pregnant women (controls) were evaluated, 15 of whom had factor V Leiden mutation, 12 had protein C/S deficiency, 30 had a repeated lupus anticoagulants, and 27 increased anticardiolipin antibodies (ACA). All carriers of factor V Leiden mutation (N=15) as well as all the patients with low activated protein C (APC) resistance ratio (N=15) had a ProC Global normalized ratio (NR) less than 0.80 (sensitivity 100%). Twenty-four patients positive for the lupus anticoagulants (LA) and 19 patients positive for ACA (>5.0 IgG U/mL) had a ProC Global NR less than 0.8, while six and eight, respectively, had a ProC Global NR greater than 0.8 (sensitivity, 70%-80%). The detection of a reduced protein C/protein S activity (<70%) was low (sensitivity, 33%-44%). In 25 cases with pathologic ProC Global results, a thrombophilic defect (protein S/LA/ACA without APC resistance) was diagnosed in 18 women; but in 7 cases, no known thrombophilic defect was present. ProC Global is a new screening test to identify patients with defects of the protein C system and an activated dotting system in preeclampsia but cannot correctly cover each thrombophilic component.
authors.affiliation: Department of Obstetrics and Gynecology, City Hospital, Ruesselsheim, Germany. dr.lothar.heilmann@t-online.de
authors.forename: Lothar
authors.initials: L
authors.lastname: Heilmann
authors.forename: Georg-Friedrich
authors.initials: GF
authors.lastname: von Tempelhoff
authors.forename: Kuhnhart
authors.initials: K
authors.lastname: Pollow
mesh_terms: D000328:Adult; D015415:Biomarkers / Q000097:blood; D001780:Blood Coagulation Tests / Q000592:standards; D016022:Case-Control Studies; D005260:Female; D017359:HELLP Syndrome / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D006801:Humans; D011225:Pre-Eclampsia / Q000097:blood / Q000175:diagnosis* / Q000209:etiology; D011247:Pregnancy; D011486:Protein C / Q000032:analysis* / Q000378:metabolism; D011933:Reagent Kits, Diagnostic / Q000592:standards*; D012680:Sensitivity and Specificity; D019851:Thrombophilia / Q000097:blood / Q000175:diagnosis
chemical_list: D015415:Biomarkers; D011486:Protein C; D011933:Reagent Kits, Diagnostic